Cymetra injection for unilateral vocal fold paralysis.
Cymetra has shown excellent tissue biocompatibility, a low rate of resorption, and no tissue reactivity when injected for treatment of facial wrinkling. On the basis of these findings, we hypothesize that injection of Cymetra into the thyroarytenoid muscle for treatment of glottal incompetence may demonstrate similar findings and lead to long-term improvement in voice quality and glottal gap closure. Ten patients with breathy dysphonia caused by unilateral vocal fold paralysis underwent transoral injection of Cymetra into the thyroarytenoid muscle. Each subject underwent preoperative and postoperative acoustic analysis, aerodynamic measures, taped voice sampling, and videostroboscopy. Significant improvements were identified in maximum phonation time, relative glottal area, and subjective judgment of glottal competency. These results were not maintained at the 3-month study interval. No significant change in quantitative or subjective voice quality was noted for the study group during the investigation. Resorption of Cymetra may play a significant role in contributing to these findings.
Karpenko
Andrew N
AN
Department of Otolaryngology-Head and Neck Surgery, Wayne State University, Detroit, Michigan 48201, USA.
Dworkin
James P
JP
Meleca
Robert J
RJ
Stachler
Robert J
RJ
D003094:Collagen / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D007821:Laryngeal Muscles; D011446:Prospective Studies; D013061:Speech Acoustics; D013997:Time Factors; D014826:Vocal Cord Paralysis / Q000150:complications / Q000628:therapy*; D014832:Voice Disorders / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D014833:Voice Quality
C471832:Cymetra; D003094:Collagen